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ABSTRACT
Introduction Systematic reviews with network meta- 
analysis (NMA; ie, multiple treatment comparisons, indirect 
comparisons) have gained popularity and grown in number 
due to their ability to provide comparative effectiveness 
of multiple treatments for the same condition. The 
methodological review aims to develop a list of items 
relating to biases in reviews with NMA. Such a list will 
inform a new tool to assess the risk of bias in NMAs, and 
potentially other reporting or quality checklists for NMAs 
which are being updated.
Methods and analysis We will include articles that 
present items related to bias, reporting or methodological 
quality, articles assessing the methodological quality of 
reviews with NMA, or papers presenting methods for 
NMAs. We will search Ovid MEDLINE, the Cochrane library 
and difficult to locate/unpublished literature. Once all items 
have been extracted, we will combine conceptually similar 
items, classifying them as referring to bias or to other 
aspects of quality (eg, reporting). When relevant, reporting 
items will be reworded into items related to bias in NMA 
review conclusions, and then reworded as signalling 
questions.
Ethics and dissemination No ethics approval was 
required. We plan to publish the full study open access 
in a peer- reviewed journal, and disseminate the findings 
via social media (Twitter, Facebook and author affiliated 
websites). Patients, healthcare providers and policy- 
makers need the highest quality evidence to make 
decisions about which treatments should be used in 
healthcare practice. Being able to critically appraise the 
findings of systematic reviews that include NMA is central 
to informed decision- making in patient care.
INTRODUCTION
Reviews with network meta- analysis (NMAs) 
have gained popularity due to their ability 
to provide comparative effectiveness of 
multiple treatments for the same condition.1 
Reviews with NMA have grown in number. 
Between 1997 and 2015, 771 NMAs were 
published in 336 journals from 3459 authors 
and 1258 institutions in 49 countries.2 More 
than three- quarters (n=625; 81%) of these 
NMAs were published in the last 5 years. 
Many organisations such as the National 
Institute for Health and Care Excellence 
(NICE) in the UK, the World Health Organi-
sation (WHO) and the Canadian Agency for 
Drugs and Technologies in Health (CADTH) 
conduct NMAs as they represent the best 
available evidence to inform clinical practice 
guidelines.3–5 We adopt a broad definition of 
NMAs, specifically: a review that aims to, or 
intends to, simultaneously synthesise more 
than two heath care interventions of interest. 
Reviews that intend to compare multiple treat-
ments with an NMA but then find that the 
assumptions are violated (eg, a disconnected 
network, or studies are too heterogeneous to 
combine) and that NMA is not feasible, will 
also be included in our definition.
Evidence shows that biased results from 
poorly designed and reported studies can 
Strengths and limitations of this study
 ► No tool for assessment of biases in reviews with 
network meta- analysis (NMA) currently exists.
 ► Our research aims to develop a list of items related 
to bias in the goal of developing the first tool for as-
sessing risk of bias in the findings of NMAs.
 ► A comprehensive and systematic process will be 
followed to develop a risk of bias tool for assess-
ing reviews with NMAs, as outlined in Whiting et 
al’s ‘Framework for Developing Quality Assessment 
Tools’, starting with this methodological review to 
develop a list of bias items used to assess NMAs
 ► One limitation is that the items identified through 
this methodological review should be considered 
as possible contenders for inclusion in the risk of 
bias in NMAs tool since items have not been vetted 
through a Delphi exercise with experts as of yet.
 ► Wording of the items may change after conducting 
the Delphi and pilot testing exercises.
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mislead decision- making in healthcare at all levels.6–9 If 
a review is at risk of bias and inappropriate methods are 
used, the validity of the findings can be compromised.10–12 
Evaluating how well a review has been conducted is essen-
tial to determining whether the findings are relevant to 
patient care and outcomes. Several empirical studies have 
shown that bias can obscure the real effects of a treat-
ment.13–16 Being able to appraise reviews with NMA is 
central to informed decision- making in patient care.
The systematic procedures required to conduct a 
systematic review help mitigate the risk of bias. However, 
bias can also be introduced when interpreting the reviews 
findings. For example, review's conclusions may not be 
supported by the evidence presented, the relevance of the 
included studies may not have been considered by review 
authors, and reviewers may inappropriately emphasise 
results on the basis of their statistical significance.17 A well- 
conducted systematic review draws conclusions that are 
appropriate to the included evidence and can therefore 
be free of bias even when the primary studies included in 
the review have high risk of bias.
Tools are available for most study designs to make 
risk of bias assessment easier for a knowledge user (eg, 
healthcare practitioners, policymakers, patients18). Many 
tools and checklists can be used either when conducting 
a systematic review (quality of conduct), when assessing 
how well a study has been described (reporting), or 
when knowledge users want to assess the risk of bias in 
the conclusions of a review. The methodological quality 
of studies (ie, how well the study is conducted) is often 
confused with reporting quality (ie, how well authors 
describe their methodology and results). A risk of bias 
assessment is an assessment of review limitations, which 
focus on the potential of those methods to bias the study 
findings.17
More than 40 tools have been identified19 20 for criti-
cally appraising the quality of reviews with pairwise meta- 
analysis. AMSTAR (A MeaSurement Tool to Assess the 
methodological quality of systematic Reviews)21 and the 
OQAQ (Overview Quality Assessment Questionnaire22) 
have been identified as the most commonly used, and 
they follow a simple checklist format.20 23 AMSTAR has 
been recently updated to AMSTAR 2, which aims to 
evaluate how reviews are planned and conducted.24 
The ROBIS (Risk Of Bias In Systematic reviews) tool is 
designed to assess the risk of bias in systematic reviews 
with or without pairwise meta- analysis.17 The ROBIS tool 
involves assessment of methodological features in reviews 
known to increase the risk of bias in review conclusions. 
Domain- based assessment tools require a careful reading 
and thoughtful analysis of the study to adequately 
rate risk of bias, instead of simply identifying keywords 
reported in the article, as usually made in a checklist type 
of assessment.
For critically appraising reviews with NMA, several 
checklists exist. To assess reporting quality, the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
statement extension for reviews incorporating network 
meta- analysis (PRISMA- NMA)25 or the National Institute 
for Health and Care Excellence Decision Support Unit 
checklist (NICE- DSU)26 can be used. To assess quality 
of conduct, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) checklist27 can 
be used. However, many quality assessment tools are not 
created rigorously. To be rigorous, they must follow a 
series of systematic steps.28 29 As a quality of conduct tool, 
the ISPOR checklist27 did not follow the methodology 
proposed by Whiting29 for creating a systematically devel-
oped quality tool. Due to important methodological 
advances in the field of NMA, the ISPOR, published in 
2014, is also outdated. As table 1 shows, several tools are 
designed with different purposes; some for assessing 
reporting quality, and some for assessing quality of conduct 
but none are designed to assess risk of bias in NMAs.
A comprehensive and systematic process should be used 
to develop a rigorous risk of bias tool for assessing NMAs, 
as outlined in Whiting et al’s29 ‘Framework for Developing 
Quality Assessment Tools’ The first step is to: (1) conduct 
a systematic search of biases that can inform the assess-
ment of the validity and reliability of NMAs and prepare a 
pilot list of items, (2) create a draft tool, (3) obtain expert 
opinion on the draft tool and inclusion of items through 
Delphi exercises, and (4) pilot test and refine the tool.29 
No review has comprehensively and systematically listed 
and categorised all items related to bias in NMAs. Such 
a list will inform a new tool to assess the risk of bias in 
NMAs, and potentially other reporting or quality tools 
which are being updated.
OBJECTIVE
Our objective for this protocol paper is to plan the 
conduct of a methodological review to develop a list of 
items relating to bias in NMAs. This is the first step in 
the goal of developing a risk of bias tool to assess NMAs. 
Further steps will involve conducting a series of Delphi 
surveys to select, refine and compile items into a tool; 
pilot test and then refine the draft tool with different user 
groups; and finally develop and evaluate an evidence- 
based (knowledge translation) KT strategy to disseminate 
the tool. This protocol pertains to our first objective to 
systematically search for and identify a list of bias items 
for NMAs.
METHODS AND ANALYSIS
We will follow the methodology proposed by Whiting,29 
Sanderson30 and Page7 for creating systematically devel-
oped lists of quality items. Although this protocol is for 
a methodological review, and not a health intervention 
review, our protocol was described and reported in accor-
dance with the preferred reporting items for systematic 
reviews and meta- analysis protocol (PRISMA- P) checklist 
with not applicable indicated for items not pertaining to 
methods reviews31 (online supplemental appendix 1).
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Eligibility criteria
There will be two types of studies included. Study type 
1 are articles that present and describe items related to 
bias, reporting or methodological quality of reviews with 
NMA. Items related to reporting will be retained because 
they can potentially be translated into a risk of bias item. 
For example, in the PRISMA- P guideline,31 one item asks 
whether study PICO (Population, Interventions, Compar-
isons, Outcomes) characteristics were used as criteria for 
determining study eligibility. Reporting of all outcomes 
in a protocol may prevent authors from only selecting 
outcomes that are statistically significant when publishing 
their systematic review. This PRISMA- P reporting item can 
then be translated into a bias item related to the ‘selective 
reporting’ of outcomes.32 Study type 2 are studies that 
assess the methodological quality in a sample of reviews 
with NMA.
Study type 1 will meet any of these inclusion criterion
 ► Articles describing items related to bias or methodo-
logical quality in reviews with NMA (eg, Dias 201833); 
tools that only assess general aspects of systematic 
reviews without focusing specifically on NMA will be 
excluded (eg, AMSTAR,21 AMSTAR 224 or ROBIS17).
 ► Articles describing editorial standards for reviews with 
NMA (eg, similar to the Cochrane MeCIR (Method-
ological standards for the conduct of new Cochrane 
Intervention Reviews) standards for systematic 
reviews34).
 ► Articles describing items related to reporting quality 
in reviews with NMA (eg, PRISMA- NMA25).
 ► Articles identifying or addressing sources of bias and 
variation in NMA and published after PRISMA- NMA 
in 2014.
Study type 2 will meet any of these inclusion criterion
 ► Articles assessing the methodological quality (or risk 
of bias) of reviews with NMA (ie, a sample of NMAs 
are assessed for methodological quality; e.g. Cham-
bers 201535) using criteria that focus specifically on 
aspects of NMA not just on general aspects of system-
atic reviews.
We will include articles with any publication status and 
in any language, and where the coauthors are not fluent 
in the language, Google Translate will be used.
If through our main search, we identify a systematic 
review encompassing the eligible articles, or one aspect of 
the eligible article, we will use the results of the systematic 
review and only include primary studies published subse-
quent to the systematic review. For example, a review by 
Laws et al in 20195 identified all guidance documents 
for conducting an NMA from countries throughout the 
world. We therefore would not search for guidance docu-
ments published before the last search date of this review.
Table 1 Tools and checklists to aid in systematic review conduct, or to assess the reporting or methodological quality of a 
review
Tool purpose
Examples 
of tools or 
checklists Description of the example checklist or tool
Available tool for 
reviews with NMA
Guidance for 
conducting 
systematic reviews
MECIR34 Detailed methodological guidance on how to conduct a systematic 
review with or without pairwise meta- analysis of effectiveness, 
diagnostic test accuracy, individual patient data reviews and 
reviews in public health and health promotion
No
Assess the quality of 
published reviews
AMSTAR-224, 
OQAQ22
AMSTAR-2 is a critical appraisal tool to assess the quality of 
conduct of reviews of randomised controlled trials of interventions
ISPOR27
Assess the risk of 
bias of published 
reviews
ROBIS17 ROBIS is a tool for assessing the risk of bias in reviews. It is 
aimed at four broad categories of reviews mainly within healthcare 
settings: interventions, diagnosis, prognosis, and aetiology.
No
Assess the certainty 
in evidence and 
the strength of 
recommendations
GRADE39 GRADE approach defines the certainty of a body of evidence as 
the extent to which one can be confident that a pooled effect 
estimate is close to the true effect of the intervention. Five domains 
assessed: risk of bias, inconsistency, indirectness, imprecision and 
publication bias.
GRADE- NMA,40 
41 CINeMA,42 
Threshold method43
Guidelines for the 
complete reporting 
published reviews
PRISMA44 PRISMA is an evidence- based minimum set of items for reporting 
in reviews and meta- analyses. PRISMA focuses on the reporting 
of reviews evaluating randomised trials, but can also be used as a 
basis for reporting reviews of other types of research, particularly 
evaluations of interventions.
PRISMA- NMA25, 
NICE- DSU26
AMSTAR-2, A Measurement Tool to Assess Systematic Reviews 2; CINeMA, Confidence in Network Meta- Analysis; GRADE, Grading of 
Recommendations Assessment, Development and Evaluation; GRADE- NMA, Grading of Recommendations Assessment, Development 
and Evaluation for Network Meta- Analysis; ISPOR, International Society for Pharmacoeconomics and Outcomes Research; MECIR, 
Methodological Expectations of Cochrane Intervention Reviews; NICE- DSU, National Institute for Health and Care Excellence Decision 
Support Unit checklist; OQAQ, Overview Quality Assessment Questionnaire; PRISMA, Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses; PRISMA- NMA, PRISMA statement extension for reviews incorporating NMA; ROBIS, Risk Of Bias In Systematic reviews.
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Search strategy
We will search Ovid MEDLINE (January 1946 to June 
2020), the Cochrane library as well as the following grey 
literature databases: the EQUATOR Network (http://
www. equator- network. org/ reportingguidelines/), Disser-
tation Abstracts, websites of evidence synthesis organ-
isations (Campbell Collaboration Cochrane Multiple 
Treatments Methods Group, CADTH, NICE- DSU, Health 
Technology Assessment International (HTAi), Pharma-
ceutical Benefits Advisory Committee, Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen, European 
Network for Health Technology Assessment, Guidelines 
International Network, ISPOR, International Network of 
Agencies for Health Technology Assessment, and JBI) as 
well as methods collections (ie, Cochrane Methodology 
Register, AHRQ Effective Healthcare Programme). We 
will validate the MEDLINE strategy by using the PubMed 
IDs of 10 included studies (identified by experts prior 
to our eligibility screening) and evaluating whether the 
strategy identified the PMIDs (online supplemental 
appendix 2).
A systematic search strategy will be developed by two 
methodologists (CL and PW) without limitations to publi-
cation type, status, language or date to identify existing 
tools or articles. An information specialist will check the 
search strategy for MEDLINE Ovid and assess it using the 
PRESS (Peer Review Electronic Search Strategies) guid-
ance.36 The full search strategies for all databases and 
websites can be found in Appendix 2. To identify other 
potentially relevant studies, we will examine the reference 
lists of included studies. We will ask experts in methods 
for NMA to identify articles missed by our search. We will 
contact authors of abstracts to retrieve the full report or 
poster.
We will search the reference section of a bibliometric 
study of reviews with NMAs37 and extract the name of the 
journals that publish NMAs. We will then contact their 
editors in chief and ask if they have any in- house editorial 
standards for reviews with NMA.
Process for screening, data extraction and analysis
The eligibility criteria will be piloted in Microsoft Excel by 
two reviewers independently on a sample of 25 citations 
retrieved from the search to ensure consistent applica-
tion. After high agreement (>70%) is achieved, the Covi-
dence38 web- based tool (https://www. covidence. org) 
will be used by two reviewers to independently screen 
the citations based on the eligibility criteria. Disagree-
ments will be discussed until consensus is reached. 
A third reviewer (CL) will arbitrate if disagreements 
cannot be resolved.
The data extraction form will be piloted by reviewers 
independently on a sample of five included papers to 
ensure consistent coding. Two independent authors 
will extract data on the characteristics of the studies and 
items. Any disagreements will be arbitrated by a third 
author.
Data extraction
The sources will first be categorised by the type of article 
coded as per our inclusion criteria. A table of tool char-
acteristics will be developed with the following headings: 
first author, year; type of tool (tool, scale, checklist or 
domain- based tool); whether the tool is designed specific 
topic areas (specify); number of items; domains within 
the tool; whether the item relates to reporting or meth-
odological quality (or other concepts such as precision, 
acceptability); how items and domains within the tool are 
rated; methods used to develop the tool (eg, review of 
items, Delphi study, expert consensus meeting) and the 
availability of an ‘explanation and elaboration’.7
Data will be extracted on items that are potentially rele-
vant to the risk of bias or quality of reviews with NMAs. 
Items will be initially extracted verbatim.
Data analysis
The following steps will be used when analysing items:
1. Map to ROBIS domains
Items will be mapped to ROBIS domains (study eligi-
bility criteria; identification and selection of studies; data 
collection and study appraisal; and synthesis and find-
ings) and specific items within the domains. The ratio-
nale for mapping items to ROBIS is that it is the only tool 
to assess risk of bias in reviews. Items that do not clearly 
map to the existing ROBIS domains will be listed sepa-
rately and grouped by similar concept. New domains may 
be created if items do not fit well into the established 
ROBIS domains.
2. Split items so that each item only covers a single 
concept
Two or more concepts grouped in one item will be split 
so that each item covers a single concept. A rationale as 
to why the item was split will be described. For example, 
PRISMA- NMA item 15 (‘Specify any assessment of risk of 
bias that may affect the cumulative evidence (eg, publi-
cation bias, selective reporting within studies)’) will be 
split into two items because this item is represented by 
two items in ROBIS in the synthesis and findings domain, 
namely ‘4.5 Were the findings robust, for example, as 
demonstrated through funnel plot or sensitivity anal-
yses?’ and ‘4.6 Were biases in primary studies minimal or 
addressed in the synthesis?”’.
3. Group similar items
Items that are conceptually similar will be grouped 
together and noted with the source. We will classify 
items as relating to bias or other aspect of quality (eg, 
reporting). When relevant, items related to reporting 
will be reworded into items related to bias in NMA review 
conclusions.
4. Omit duplicate items (but keep these in a column in 
the table for transparency)
If items are worded vaguely or are unexplained, we will 
use an iterative process to interpret the item and ensure 
that there is a mutual understanding of the item between 
authors when coding. The process will be iterative, and 
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if any gaps in items related to bias in reviews of NMA are 
identified, a new item will be inferred.
The final list of items deemed unique will be retained. 
We will reword items as signalling questions, where an 
answer of ‘yes’ suggests the absence of bias. We will provide 
examples to illustrate the items and write a rationale and 
description of each item. These items will be submitted 
in a multiround Delphi exercise by NMA experts who will 
give their opinion about each item’s potential inclusion 
in the tool.
We will count the number of sources and unique 
items included. We will summarise the characteristics of 
included tools in tables and figures. We will calculate the 
median and IQR of items across all tools and tabulate the 
frequency of different biases identified in the tools.
Patient and public involvement
Patients or the public were not involved in the design of 
our research protocol.
ETHICS AND DISSEMINATION
No ethics approval was required as no human subjects 
were involved. Our research aims to develop a list of items 
related to bias in the goal of developing the first tool for 
assessing risk of bias in the findings of reviews with NMA. 
We plan to publish the full study open access in a peer- 
reviewed journal, and disseminate the findings via social 
media (Twitter, Facebook and author affiliated websites).
Patients, healthcare providers and policy- makers need 
the highest quality evidence to make decisions about 
which treatments should be used in healthcare practice. 
Being able to critically appraise the findings of reviews 
with NMA is central to evidenced- based decision- making 
in patient care.
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